NOVARTIS AG (NY:NVS)

View All ReportsStreetInsider.com Reports on NVS

Feb 9, 2010 09:11 AM Novartis (NVS) Gains Rights to Develop and Distribute Debio 025; Currently in Phase IIb

Feb 8, 2010 07:09 AM SciClone Pharma (SCLN) and Partner Announce Topline Results for ZADAXIN

Jan 26, 2010 08:24 AM Novartis (NVS) Reports Rise In Profits and Names New CEO

Jan 21, 2010 01:12 PM Teva (TEVA) Gets Tenative Approval From U.S. FDA for Generic Version of Novartis' (NVS) Femara Tablets

Jan 20, 2010 10:42 AM Notable Mergers and Acquisitions of the Day 1/20: CAMD/ONNN, ACL/NVS, XRX

View All Press ReleasesCompany Press Releases on NVS

Feb 3, 2010 08:30AM Tasigna Front Line Data Convincing But Not Enough to Displace Gleevec

Jan 26, 2010 07:00AM Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.

Jan 25, 2010 06:03AM Four Worksites Awarded CEO Cancer Gold StandardTM Accreditation

Jan 21, 2010 06:50AM Biotech Stock Alert for GenVec Inc. Issued by Beacon Equity

Jan 19, 2010 11:49AM Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products

StreetInsider Reports on NVS by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on NVS

Feb 9, 2010 01:25 PM Amgen Sees Positive Results from Osteoporosis Drug

Feb 1, 2010 06:55 AM Novartis Makes Notable CEO Pick

Jan 26, 2010 03:50 PM Novartis 2009 Annual Conference Call Transcript

Jan 26, 2010 03:52 AM GenVec's Hearing Loss Program Gets Welcome Boost from Novartis

Jan 25, 2010 11:27 AM Report from Europe: Bears Come Out of Hibernation

View All FilingsSEC Filings on NVS

Feb 9, 2010 12:02PM Form 6-K NOVARTIS AG For: Feb 09

Feb 9, 2010 06:16AM Form 6-K NOVARTIS AG For: Feb 09

Jan 26, 2010 12:23PM Form 6-K NOVARTIS AG For: Jan 26

Jan 22, 2010 06:16AM Form 6-K NOVARTIS AG For: Jan 20

Jan 22, 2010 06:16AM Form 6-K NOVARTIS AG For: Jan 20

View All Comments Comments on recent NVS articles

WEL
on Jan 15, 2010
at 08:22 PM MAXIDEX DEXAMETHASONE wARNINg I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES MAXIDEX REACTION to verify Or call 800-757-9195
Article: Brower Piven Announces Investigation of Alcon, Inc.

WEL
on Jan 15, 2010
at 08:13 PM MAXIDEX DEXAMETHASONE wARNINg I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES MAXIDEX REACTION to verify Or call 800-757-9195
Article: / CORRECTION - Shareholders File Lawsuit Against Novartis & Alcon Over Merger -- KSF Announces Lawsuit

Carol G. Ruzicka
on Jan 15, 2010
at 02:51 PM NVS ACL Association How is the ACL buy going to effect NVS stock? ACL seems to be in a bit of admin. mess.
Article: Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Alcon Inc.

James Fillion
on Jan 12, 2010
at 06:44 AM TTNP's royalty It is 8% on first $200M.
Article: Novartis (NVS) Launches Vanda Pharma's (VNDA) Fanapt Schizophrenia Treatment

George
on Jan 12, 2010
at 12:44 AM Novartis Fanapt Launch You neglecyed to mention Titan Pharmaceuticals (TTNP) in the article. Titan licensed Fanapt to Novartis. Novartis then sublicensed it to Vanda. Titan will collect royalties on all future sales: 5% of sales up to $200 million and 10% of sales above $200 million.
Article: Novartis (NVS) Launches Vanda Pharma's (VNDA) Fanapt Schizophrenia Treatment

Comments on NVS

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?